GSK presents Phase 2b data on linerixibat for the treatment of ...
2. US Census & CDC reported immunisation rate. 3. US Census & IQVIA Patient Data Analysis (Estimated % of adults who have received vaccinations ...
acting HIV treatments; positive phase II data on N6LS broadly ... the phase III trial of linerixibat for cholestatic pruritus in.
... stage pipeline with regulatory approvals, positive data read-outs and strategic business development. 69 vaccines and specialty medicines.
– Data from Phase 2b study vs SoC expected in 2022. L o g. 1. 0 ch a n ... Targeted treatments for rheumatoid arthritis, Novel treatment ...
... phase IIb data for bepirovirsen. Cost discipline supports delivery of ... medicines and vaccines in late-stage (phase III) development by therapy ...
of supply of the vaccine. Other Pharmaceuticals. Linerixibat. • Phase IIb data on linerixibat for the treatment of cholestatic pruritus in ...
– Data from Phase 2b study vs SoC expected in 2022. L o g. 1. 0 ch a n ... Targeted treatments for rheumatoid arthritis, Novel treatment ...
In 2023, positive phase III data showed it has the potential to be the first in a new class of oral antibiotics for uUTI in over 20 years ...
candidate and innovative MAPSTM technology. • Promising phase IIb interim data presented for bepirovirsen, a potential new treatment for chronic ...
... treatment for children living with HIV 5.China's National Medical ... Phase 2b data 14. Hepatitis B virus. ^Tesaro asset. Page 8. Growth ...
B-Together (hepatitis B virus) Phase IIb data readout daprodustat. ASCEND (anaemia of chronic kidney disease). Regulatory decision. (US, EU).
Share of US triple therapy patients (COPD1)2. 0%. 10 %. 20 %. 30 ... Phase IIb data 7. Hepatitis B virus 8. Potentially registrational 9 ...
Early treatment of COVID-19 REGEN-COV, bamlanivimab/ etesevimab ... Quarter 2 results announcement. 31 July 2024. Quarter 3 results ...
... Data File required to be submitted pursuant to. Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for ...
The calculation of Adjusted results is described on page 56. Financial record. Page 3. GSK Annual Report 2021 259. Strategic report.
that an anti-IL5 biologic had reported positive phase III data in CRSwNP. We also submitted regulatory applications in. Europe for the use of ...
Indicate by check mark whether the registrant (1) has filed all reports to be filed by Section 13 or 15(d) of the Securities Exchange Act of ...
Three year financial data is presented reflecting the restated results following the demerger of the Consumer Healthcare business. The financial ...
• Alector presented positive data from the INFRONT-2 Phase II open-label trial of AL001 for the treatment of symptomatic frontotemporal ...
hepatitis B surface antigen after four weeks of treatment. We anticipate data from our ongoing phase IIb programme in 2022. Cytomegalovirus.